NCT01833039Approved For Marketing不适用
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.
排除标准
- •Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.
- •Patients previously treated with ibrutinib are not eligible.
- •Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.
研究者
相似试验
已完成
不适用
Ibrutinib for Relapsed or Refractory Mantle Cell LymphomaMantle Cell LymphomaNCT04061850Samsung Medical Center88
已完成
2 期
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaRelapsed/Refractory Mantle Cell LymphomaNCT02460276Lund University Hospital50
No Longer Available
不适用
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-HodgkinLymphoma, T-Cell, CutaneousNCT01196208Seagen Inc.
已完成
1 期
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseaseGraft Versus Host DiseaseNCT02195869Pharmacyclics LLC.45
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib TherapyMantle Cell LymphomaNCT01599949Janssen Research & Development, LLC120